Welcome to our dedicated page for Black Diamond Therapeutics SEC filings (Ticker: BDTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Black Diamond Therapeutics filings document financial results, clinical-program disclosures and governance matters for a Nasdaq-listed clinical-stage oncology company. Recent Form 8-K reports furnish quarterly and annual operating results and corporate updates tied to silevertinib, the company’s EGFR MasterKey inhibitor program for EGFR-mutant NSCLC and glioblastoma, along with liquidity and capital-expenditure commentary.
Proxy materials disclose annual meeting matters, including board-class elections, auditor ratification, advisory executive-compensation votes and the preferred frequency of future compensation votes. The filings also identify the company’s registered common stock, par value and Nasdaq Global Select Market listing under the BDTX symbol.
Black Diamond Therapeutics, Inc. reported the results of its 2026 annual stockholder meeting. Of 57,301,774 common shares entitled to vote as of April 28, 2026, 44,690,495 were represented, establishing a quorum. Stockholders elected Shannon Campbell and Kapil Dhingra as Class III directors for three-year terms. They also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026. Stockholders approved, on a non-binding basis, the compensation of the named executive officers and indicated a preference to hold this advisory vote every year. The company will conduct future say-on-pay votes annually until the next required vote on frequency.
Behbahani Ali reported acquisition or exercise transactions in this Form 4 filing.
Black Diamond Therapeutics director Ali Behbahani received a grant of 8,961 shares of common stock at $1.66 per share. These shares were issued under the company’s Sixth Amended and Restated Non-Employee Director Compensation Policy, in which he elected stock instead of cash for annual board service.
After this award, Behbahani directly holds 102,529 shares of common stock. Separately, 4,448,757 shares are reported as indirectly held by New Enterprise Associates 16, L.P., where he is affiliated through general partner entities. He disclaims beneficial ownership of portions of those indirect holdings in which he has no pecuniary interest.
Raman Prakash reported acquisition or exercise transactions in this Form 4 filing.
Black Diamond Therapeutics director Raman Prakash received 7,907 shares of common stock as equity compensation. The shares were granted in lieu of cash fees under the company’s Sixth Amended and Restated Non-Employee Director Compensation Policy at a reference price of $1.66 per share, based on the June 18, 2026 closing price. Following this award, Prakash directly holds 45,039 shares.
Black Diamond Therapeutics filed an 8-K to share positive Phase 2 results for silevertinib as a frontline treatment for non-small cell lung cancer patients with EGFR non-classical mutations. The trial enrolled 43 treatment‑naïve patients at a 200 mg once‑daily oral dose, including 19 with brain metastases and seven with measurable CNS lesions.
As of an April 11, 2026 data cutoff, median follow‑up was 11.2 months and the study is ongoing. Management highlights robust preliminary progression‑free survival that they say far exceeds historical data for available therapies, and notes silevertinib prevented development of de novo brain metastases in this population. The data will be presented at the 2026 ASCO Annual Meeting and discussed on a company webcast for investors.
Black Diamond Therapeutics, Inc. reported a net loss of $9.0 million for the quarter ended March 31, 2026, compared with net income of $56.5 million a year earlier, when it recorded a $70.0 million upfront license payment from Servier.
Research and development expense declined to $7.0 million from $10.5 million, reflecting lower NSCLC spending and the out‑licensing of BDTX‑4933, partially offset by higher GBM costs. General and administrative expense fell to $4.3 million from $5.0 million due to operational efficiencies.
The company ended the quarter with $118.3 million in cash, cash equivalents and investments and expects this to fund operations into the second half of 2028. Lead EGFR inhibitor silevertinib is in Phase 2 trials for NSCLC and newly diagnosed EGFR‑altered glioblastoma.
Black Diamond Therapeutics, Inc. reported first quarter 2026 results, showing a net loss of $9.0 million after earning $56.5 million in the same period of 2025, mainly because prior-year license revenue of $70.0 million did not recur. Cash, cash equivalents and investments were $118.3 million as of March 31, 2026, and the company believes this will fund operations into the second half of 2028. R&D and G&A expenses declined year over year as the company sharpened its focus on silevertinib. Clinically, Black Diamond dosed the first patient in its randomized Phase 2 trial of silevertinib in newly diagnosed EGFRvIII+ GBM and plans multiple silevertinib data presentations at the 2026 ASCO Annual Meeting.
Black Diamond Therapeutics, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 26, 2026. The agenda includes electing two Class III directors to serve until 2029, ratifying PricewaterhouseCoopers LLP as auditor for 2026, and two advisory votes on executive pay and how often future “Say‑on‑Pay” votes should occur.
Only holders of the company’s common stock at the close of business on April 28, 2026, when 57,301,774 shares were outstanding, may vote. Stockholders can vote online, by telephone, by mail, or during the live webcast. The board recommends voting in favor of all proposals and for an annual Say‑on‑Pay frequency.
Behbahani Ali reported acquisition or exercise transactions in this Form 4 filing.
Black Diamond Therapeutics director Ali Behbahani received a grant of 6,919 shares of common stock on March 20, 2026. The award was made under the company’s non-employee director compensation policy, as he elected to take stock instead of cash fees for his annual board service.
The grant was valued at $2.15 per share, based on the closing market price on March 19, 2026. After this award, Behbahani directly holds 93,568 common shares. The filing also reports 4,448,757 shares held indirectly through New Enterprise Associates 16, L.P., where he disclaims beneficial ownership for portions in which he has no pecuniary interest.
Raman Prakash reported acquisition or exercise transactions in this Form 4 filing.
Black Diamond Therapeutics director Raman Prakash received 6,105 shares of Common Stock as compensation. The shares were issued under the company’s non-employee director compensation policy, where he elected stock instead of cash for annual board service. The grant was valued at $2.15 per share, bringing his direct holdings to 37,132 shares.